BOSTON, March 24, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present data from its four late-stage programs in epilepsy and movement disorders at the American Academy of Neurology (AAN) 2025 Annual Meeting taking place from April 5 to 9, 2025 in San Diego, California.
“Praxis’s innovative pipeline continues to rapidly advance, with four late-stage programs poised to transform patient care,” said Steven Petrou, Chief Scientific Officer and Co-Founder of Praxis. “At this year’s AAN, we’re excited to present the latest developments…